Highbridge Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Highbridge Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-150,000	Closed	-$3.25M	–	1960
2017 Q2	$3.25M	Buy	150,000 +100,897	+205%	+$1.83M	0.05%	373
2017 Q1	$688K	Buy	+49,103	New	+$804K	0.01%	766
2016 Q3	–	Sell	-69,725	Closed	-$937K	–	1871
2016 Q2	$937K	Buy	+69,725	New	+$1.02M	0.02%	633
2013 Q4	–	Sell	-31,622	Closed	-$408K	–	1470
2013 Q3	$408K	Sell	31,622 -137,540	-81%	-$1.69M	﹤0.01%	944
2013 Q2	$2.01M	Buy	+169,162	New	+$1.83M	0.02%	492

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Highbridge Capital Management's AMRI Position: Q3 2017 in Review

Highbridge Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 150,000 shares — an estimated $3.25M sold.

Highbridge Capital Management first reported a position in AMRI in Q2 2013 and held it in 5 quarters. The position peaked at $3.25M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Highbridge Capital Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Highbridge Capital Management sold 150,000 Albany Molecular Research Inc shares in Q3 2017, an estimated $3.25M.
Highbridge Capital Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 5 quarters.
Highbridge Capital Management's Albany Molecular Research Inc position peaked at $3.25M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.